Felycin-CA1 (Sirolimus Delayed-Release Tablets) for Cats 0.4mg 12 Tablets

Felycin-CA1 (Sirolimus Delayed-Release Tablets) for Cats 0.4mg 12 Tablets
Processing...
List Price: $59.99
Sale Price: $53.39
Code: 30091693
Qty
Enter pet & vet info at checkout
  • Let us contact your vet for you
  • Have your vet call or fax us
  • Mail us the original prescription

Product Info:

Felycin‑CA1 is a once‑weekly sirolimus delayed‑release tablet used in cats with subclinical hypertrophic cardiomyopathy (HCM). It helps manage ventricular hypertrophy by slowing the abnormal thickening of the heart muscle associated with subclinical HCM. This medication is conditionally approved by the FDA for this specific use. Felycin-CA1 requires a prescription from your veterinarian.

For:

Cats (Over 5.5 lbs, with subclinical Hypertrophic Cardiomyopathy)

Benefits:

  • The first FDA conditionally-approved drug for the management of ventricular hypertrophy in cats with subclinical HCM.
  • Felycin-CA1 is administered orally once-a-week for cats in small tablet sizes.
  • Offers early intervention for cats with subclinical HCM.
  • An affordable treatment option to manage subclinical HCM.
  • Available in three strengths to ensure accurate administration for maximum efficacy.

Storage:

Store in a cool, dry place between 68 F - 77 F (20 C - 25 C). Excursions between 59 F - 86 F (15 C - 30 C) are permitted. Keep Felycin-CA1 in a secure location out of reach of dogs, cats and other animals to prevent accidental ingestion of overdose. Keep out of reach of children. Contact a physician in case of accidental ingestion by humans.

Cautions:

Felycin-CA1 is a prescription medication that requires veterinary authorization before use. Do not use in cats diagnosed with diabetes mellitus, as usage has been linked to fatal diabetic ketoacidosis. Do not administer in cats with pre-existing liver disease. If a cat is diagnosed with diabetes at any point during the course of treatment, the medication must be discontinued immediately.

Side Effects:

The most frequently observed adverse reactions in cats treated with Felycin-CA1 were cardiovascular in nature, relating to the progression of HCM, and included arrhythmia, congestive heart failure, syncope, and pericardial effusion. Other adverse reactions observed were lethargy, vomiting, diarrhea, and a lack of appetite. Treatment has been associated with the elevation of transaminase enzymes, specifically alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and owners should monitor for clinical signs of liver dysfunction. Bloodwork should be repeated 1 to 2 months following initiation of treatment, and every 6 to 12 months thereafter. Discontinue treatment if transaminase values exceed 2X the upper limit of normal (ULN), if other liver enzymes besides ALT or AST are elevated, or if clinical signs of liver dysfunction are noted.